Evidence map›Paper›PMID 42088601›Full record

ArticlePhysics and imaging in radiation oncology2026

Comparison of gantry-less magnetic resonance guided proton therapy with photon therapy for hepatocellular carcinoma patients.

Franciska Lebbink, Emilie Alvarez Michael, Anna Kornek, Annika Lattermann, Chiara Valentini, Petra Trnkova, Esther G C Troost

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Franciska LebbinkOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Emilie Alvarez MichaelOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Anna KornekOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Annika LattermannOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Chiara ValentiniOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Petra TrnkovaOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Esther G C TroostOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWith magnetic resonance imaging (MRI), soft-tissue tumors such as hepatocellular carcinoma (HCC) are visualised. MR guided proton therapy (MRgPT) may combine the advantages of proton therapy with soft-tissue image-guidance. Therefore, we assessed the calculated dose differences between MR-guided photon therapy (MR-LINAC) and MRgPT at a horizontal beamline for HCC patients, considering non-adapted and adapted plans. MATERIALS AND

methodsPlanning computed tomography and T2-weighted MRI of ten HCC patients with 13 lesions were included. Adaptive hypofractionated MR-LINAC, gantry-based PT as well as MRgPT treatment plans at a horizontal beamline were optimized using RayStation 2023B-R on the daily MRIs. The comparison included various dose-volume-histogram (DVH) parameters of target volumes and normal tissue.

resultsClinical target volume (CTV) coverage could be fulfilled for 12/13 cases, where plan adaptation was required for 41, 36 and 15 out of 65 fractions for MRgPT, gantry-based PT and MR-LINAC, respectively. With plan adaptation, the

conclusionsMore than half of the proton fractions needed plan adaptation for adequate target coverage. MRgPT lead to clinically acceptable treatment plans for HCC patients and reduced the dose to the uninvolved liver compared to MR-LINAC, with similar target coverage. HCC may thus be a promising indication for hypofractionated adaptive MRgPT.

Identifiers

PMID42088601
PMCPMC13137213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.